These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 23936011)

  • 1. Glycogen phosphorylase inhibitor N-(3,5-dimethyl-Benzoyl)-N'-(β-D-glucopyranosyl)urea improves glucose tolerance under normoglycemic and diabetic conditions and rearranges hepatic metabolism.
    Nagy L; Docsa T; Szántó M; Brunyánszki A; Hegedűs C; Márton J; Kónya B; Virág L; Somsák L; Gergely P; Bai P
    PLoS One; 2013; 8(7):e69420. PubMed ID: 23936011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucose-derived spiro-isoxazolines are anti-hyperglycemic agents against type 2 diabetes through glycogen phosphorylase inhibition.
    Goyard D; Kónya B; Chajistamatiou AS; Chrysina ED; Leroy J; Balzarin S; Tournier M; Tousch D; Petit P; Duret C; Maurel P; Somsák L; Docsa T; Gergely P; Praly JP; Azay-Milhau J; Vidal S
    Eur J Med Chem; 2016 Jan; 108():444-454. PubMed ID: 26708111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycogen phosphorylase as a target for type 2 diabetes: synthetic, biochemical, structural and computational evaluation of novel N-acyl-N´-(β-D-glucopyranosyl) urea inhibitors.
    Kantsadi AL; Parmenopoulou V; Bakalov DN; Snelgrove L; Stravodimos GA; Chatzileontiadou DS; Manta S; Panagiotopoulou A; Hayes JM; Komiotis D; Leonidas DD
    Curr Top Med Chem; 2015; 15(23):2373-89. PubMed ID: 26088352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crystallographic and computational studies on 4-phenyl-N-(beta-D-glucopyranosyl)-1H-1,2,3-triazole-1-acetamide, an inhibitor of glycogen phosphorylase: comparison with alpha-D-glucose, N-acetyl-beta-D-glucopyranosylamine and N-benzoyl-N'-beta-D-glucopyranosyl urea binding.
    Alexacou KM; Hayes JM; Tiraidis C; Zographos SE; Leonidas DD; Chrysina ED; Archontis G; Oikonomakos NG; Paul JV; Varghese B; Loganathan D
    Proteins; 2008 May; 71(3):1307-23. PubMed ID: 18041758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FR258900, a novel glycogen phosphorylase inhibitor isolated from Fungus No. 138354. II. Anti-hyperglycemic effects in diabetic animal models.
    Furukawa S; Murakami K; Nishikawa M; Nakayama O; Hino M
    J Antibiot (Tokyo); 2005 Aug; 58(8):503-6. PubMed ID: 16266121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucose analog inhibitors of glycogen phosphorylases as potential antidiabetic agents: recent developments.
    Somsák L; Nagya V; Hadady Z; Docsa T; Gergely P
    Curr Pharm Des; 2003; 9(15):1177-89. PubMed ID: 12769745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-(4-Substituted-benzoyl)-N'-(β-d-glucopyranosyl)ureas as inhibitors of glycogen phosphorylase: Synthesis and evaluation by kinetic, crystallographic, and molecular modelling methods.
    Nagy V; Felföldi N; Kónya B; Praly JP; Docsa T; Gergely P; Chrysina ED; Tiraidis C; Kosmopoulou MN; Alexacou KM; Konstantakaki M; Leonidas DD; Zographos SE; Oikonomakos NG; Kozmon S; Tvaroška I; Somsák L
    Bioorg Med Chem; 2012 Mar; 20(5):1801-16. PubMed ID: 22325154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The experimental type 2 diabetes therapy glycogen phosphorylase inhibition can impair aerobic muscle function during prolonged contraction.
    Baker DJ; Greenhaff PL; MacInnes A; Timmons JA
    Diabetes; 2006 Jun; 55(6):1855-61. PubMed ID: 16731853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycogen phosphorylase inhibitor, 2,3-bis[(2E)-3-(4-hydroxyphenyl)prop-2-enamido] butanedioic acid (BF142), improves baseline insulin secretion of MIN6 insulinoma cells.
    Nagy L; Béke F; Juhász L; Kovács T; Juhász-Tóth É; Docsa T; Tóth A; Gergely P; Somsák L; Bai P
    PLoS One; 2020; 15(9):e0236081. PubMed ID: 32960890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of N-glucopyranosidic derivatives as potential inhibitors that bind at the catalytic site of glycogen phosphorylase.
    Gimisis T
    Mini Rev Med Chem; 2010 Oct; 10(12):1127-38. PubMed ID: 20716054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of N-acetyl-N '-beta-D-glucopyranosyl urea and N-benzoyl-N '-beta-D-glucopyranosyl urea to glycogen phosphorylase b: kinetic and crystallographic studies.
    Oikonomakos NG; Kosmopoulou M; Zographos SE; Leonidas DD; Chrysina ED; Somsák L; Nagy V; Praly JP; Docsa T; Tóth B; Gergely P
    Eur J Biochem; 2002 Mar; 269(6):1684-96. PubMed ID: 11895439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, in vitro ADME profiling and in vivo pharmacological evaluation of novel glycogen phosphorylase inhibitors.
    Miao GX; Wang YD; Yan ZW; Zhang LY
    Bioorg Med Chem Lett; 2020 Jul; 30(14):127117. PubMed ID: 32527535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycogen phosphorylase as a molecular target for type 2 diabetes therapy.
    Oikonomakos NG
    Curr Protein Pept Sci; 2002 Dec; 3(6):561-86. PubMed ID: 12470212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. D-pinitol attenuates the impaired activities of hepatic key enzymes in carbohydrate metabolism of streptozotocin-induced diabetic rats.
    Sivakumar S; Subramanian SP
    Gen Physiol Biophys; 2009 Sep; 28(3):233-41. PubMed ID: 20037188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium caprate augments the hypoglycemic effect of berberine via AMPK in inhibiting hepatic gluconeogenesis.
    Zhang M; Lv X; Li J; Meng Z; Wang Q; Chang W; Li W; Chen L; Liu Y
    Mol Cell Endocrinol; 2012 Nov; 363(1-2):122-30. PubMed ID: 22922125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo.
    Martin WH; Hoover DJ; Armento SJ; Stock IA; McPherson RK; Danley DE; Stevenson RW; Barrett EJ; Treadway JL
    Proc Natl Acad Sci U S A; 1998 Feb; 95(4):1776-81. PubMed ID: 9465093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosiglitazone promotes fatty acyl CoA accumulation and excessive glycogen storage in livers of mice without adiponectin.
    Zhou M; Xu A; Lam KS; Tam PK; Che CM; Chan L; Lee IK; Wu D; Wang Y
    J Hepatol; 2010 Dec; 53(6):1108-16. PubMed ID: 20828853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycogen phosphorylase inhibitors.
    Henke BR; Sparks SM
    Mini Rev Med Chem; 2006 Aug; 6(8):845-57. PubMed ID: 16918491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and evaluation of novel benzazepinone derivatives as glycogen phosphorylase inhibitors with potent activity.
    Wang Y; Yan Z; Guo Y; Zhang L
    Future Med Chem; 2021 May; 13(10):897-909. PubMed ID: 33906369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and anti-hyperglycaemic efficacy of a novel inhibitor of glycogen phosphorylase, 1,4-dideoxy-1,4-imino-d- arabinitol, in glucagon-challenged rats and dogs and in diabetic ob/ob mice.
    Mackay P; Ynddal L; Andersen JV; McCormack JG
    Diabetes Obes Metab; 2003 Nov; 5(6):397-407. PubMed ID: 14617225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.